Lupin gets USFDA nod for generic version of Valeant’s Xenazine

Pharma major Lupin said it received final approval for to launch a generic version of Valeant Pharmaceuticals’ Xenazine in the US.

Tetrabenazine Tablets, 12.5 mg and 25 mg, has annual sales of approximately USD 288.1 million in the US, according to IQVIA.

The tablet is indicated for the treatment of chorea, or involuntary movements associated with Huntington’s disease.

Huntington’s disease (HD) is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain.

It deteriorates a person’s physical and mental abilities during their prime working years and has no cure.

Every child of a parent with HD has a 50/50 chance of carrying the faulty gene.

There are an estimated 30,000 Americans suffering from the disease.

India-based Lupin is the fourth largest pharma player in the US by prescription.

It focuses on Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and is considered a leader in TB treatments globally.